XPO1 and neoplasm: Pharmacologic inhibition of XPO1 with selective inhibitors such as selinexor disrupts multiple oncogenic pathways, restores tumor suppressor activity, modulates the tumor microenvironment, and enhances responses to standard therapies, including targeted agents and adoptive immunotherapies.